- Androgen ablation could benefit irradiated PCa patients. Tennant, Scott // Urology Times;Oct98, Vol. 26 Issue 10, p7
Focuses on the benefit of androgen suppression to patients in biochemical relapse following radiotherapy for localized prostate cancer. Details on the study on androgen ablation; Comments from Laurence H. Klotz, associate professor of surgery at the University of Toronto.
- Long-term ADT, high-dose radiation improved outcomes in high-risk prostate cancer. // Hem/Onc Today;8/25/2013, Vol. 14 Issue 16, p30
The article reports on the results of a retrospective analysis on the efficacy of androgen deprivation therapy (ADT) and high-dose radiation in improving outcomes in men with high-risk prostate cancer.
- Long-term androgen therapy plus XRT improves outcomes. Newman, Laura // Urology Times;Mar2001, Vol. 29 Issue 3, p12
Reports on the benefits from long-term androgen therapy plus external beam radiation for prostate cancer. Better suppression outcomes; Poor-prognosis follow-up.
- Radiotherapy Added to ADT Is Beneficial. // Renal & Urology News;May2012, Vol. 11 Issue 5, p11
The article offers information on the randomized study conducted by Nicolas Mottet Clinique of Mutualiste in St. Etienne, France which reveals that adding radiotherapy to androgen deprivation therapy (ADT) helps to improve outcome in advanced prostate cancer (PCa) patients.
- Short-Term ADT Plus RT For PCa Boosts Survival. // Renal & Urology News;Sep2011, Vol. 10 Issue 9, p9
The article reports on the findings of a study which reveals that the use of androgen deprivation therapy (ADT) for two months before and during radiation therapy (RT) for early prostate cancer (PCa) is associated with increased overall survival and decreased disease-specific mortality.
- National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer. Cooperberg, Matthew R.; Grossfeld, Gary D.; Lubeck, Deborah P.; Carroll, Peter R. // JNCI: Journal of the National Cancer Institute;7/02/2003, Vol. 95 Issue 13, p981
Background: Recent reports have suggested that growing numbers of patients with localized prostate cancer are receiving androgen deprivation therapy as primary or neoadjuvant treatment, yet sparse clinical evidence supports the use of such treatment except among patients with high-risk or...
- ADT plus radiation better than ADT alone in locally advanced prostate cancer. Harris, Jason // Hem/Onc Today;6/25/2010, Vol. 11 Issue 12, p65
The article focuses on a study which concluded that combined radiation therapy and androgen deprivation therapy reduces the risk for disease-specific death in men with locally advanced or high-risk prostate cancer.
- Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression. Pervez, N.; Krauze, A.V.; Yee, D.; Parliament, M.; Mihai, A.; Ghosh, S.; Joseph, K.; Murtha, A.; Amanie, J.; Kamal, M.; Pearcey, R. // Current Oncology;Jun2012, Vol. 19 Issue 3, pe201
Purpose We examined the impact of hypofractionated radiation therapy and androgen suppression therapy (AST) on quality of life (QOL) in high-risk prostate cancer patients. Methods Between March 2005 and March 2007, 60 patients with high-risk prostate cancer were enrolled in a prospective phase...
- Addition of radiation to ADT improved OS in locally advanced prostate cancer. Trump, Donald L. // Hem/Onc Today;12/10/2011, Vol. 12 Issue 23, p40
The article discusses research being done on the benefit of a combined treatment with androgen deprivation therapy plus radiation therapy in improving overall survival among men with locally advanced prostate cancer, referencing a study by P. Warde et al., published in a 2011 issue of "Lancet."